You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Reassurance, Refunds & Replacements

If your product does not perform as described on this datasheet, we will refund or replace your product...

Read our guarantee »
 

Anti-CD5 + CD19 antibody [CRIS1 + CB19] (Dual color: FITC + PE) (ab1235)

CodeSizePriceAbpointsAvailability
    
 
  • -
  •   
  •   
  •   
  •  
  •   
  •   
Updating...

Overview

Product name

Anti-CD5 + CD19 antibody [CRIS1 + CB19] (Dual color: FITC + PE)
See all CD5 + CD19 products (3) ...

Description

Mouse monoclonal [CRIS1 + CB19] to CD5 + CD19 (Dual color: FITC + PE)

Conjugation

Dual color: FITC + PE

Tested applications

Flow Cytmore details

Cross reactivity

Reacts with

Human

General notes

This product is a mixture of two clones: CD5 = Clone:CRIS1, Isotype:IgG2a, Label:FITC CD19 = Clone:CB19, Isotype:IgG1, Label:PE

Properties

Form

Liquid

Storage instructions

Store at +4°C in the dark. Do not freeze.

Storage buffer

Preservative: 0.1% Sodium Azide
Constituents: PBS, 0.5% BSA

Concentration

Concentration information loading...

Primary antibody notes

CD5 is a 67kDa human T-lymphocyte single-chain transmembrane glycoprotein. It is present on all mature T-lymphocytes, on most of thymocytes and on many T-cell leukemias and lymphomas. It also reacts with a subpopulation of activated B-cells. CD19: This antigen (MW = 95kDa) is present on 10-15% of human peripheral blood lymphocytes andapproximately 60% of splenic lymphocytes. It is not expressed on T lymphocytes, granulocytes, activated T cells or monocytes. Moreover, CD19 is present on principal acute and chronic B cell leukemias and lymphomas.

Clonality

Monoclonal

Clone number

CRIS1 + CB19

Myeloma

unknown

Light chain type

unknown

Applications

Show applications key

Our Abpromise guarantee covers the use of ab1235 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Flow Cyt

     

Application notes

Counting and identification of peripheral blood T CD5+ lymphocytes (CD5+/CD19-) in human lysed whole peripheral blood or mononuclear cells separated by density gradient.
Counting and identification of peripheral blood B lymphocytes (CD5-/CD19+ andCD5+/CD19+).
Counting and identification of peripheral blood B1 lymphocytes (CD5+/CD19+).
Characterization of CLL and lymphomas (CD5+/CD19+).

CD5(FITC) / CD19 (PE) immunofluorescence analysis can be performed on a flow cytometerequipped with an excitation source of 488nm and fitted with logarithmic amplifiers.

10µl ofCD5(FITC) / CD19 (PE) is sufficient for labelling 1x106 cells.

Target

Relevance

CD5 is a 67kDa single-chain transmembrane glycoprotein expressed on mature T lymphocytes, most thymocytes and B lymphocytes subset (B-1a lymphocytes) and on many T-cell leukemias and lymphomas. It is a type I membrane glycoprotein whose extracellular region contains three scavenger receptor cysteine-rich (SRCR) domains. The CD5 is a signal transducing molecule whose cytoplasmic tail is devoid of any intrinsic catalytic activity. CD5 modulates signaling through the antigen-specific receptor complex (TCR and BCR). CD5 may serve as a dual receptor, giving either stimulatory or inhibitory signals depending both on the cell type and development stage. In thymocytes and B1a cells seems to provide inhibitory signals, in peripheral mature T lymhocytes it acts as a costimulatory signal receptor. CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. The CD19 molecule is expressed on 100% of the peripheral B cells as defined by expression of kappa or lamda light chains. It is expressed on approximately 10% of normal human peripheral blood cells and approximately 60% of splenic lymphocytes. It is not expressed on granulocytes, monocytes or T cells as defined by CD3 expression. CD19 defines a pan B antigen which is expressed from the earliest stages of B progenitor development, but is lost on terminal differentiation to plasma cells. It may also be present on some early myeloid progenitors, particularly those of the monoblastic type. The CD19 antigen is expressed on approximately 12% of peripheral blood lymphocytes. It appears to be expressed on myeloid leukemia cells, particularly those of monocytic lineage. Leukemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen.

Cellular localization

Membrane; single-pass type I membrane protein.

Alternative names

  • B4 antibody
  • CD19 antibody
  • CD19 antigen antibody
  • CD19 molecule antibody
  • CD5 antibody
  • CD5 antigen antibody
  • CD5 molecule antibody
  • LEU1 antibody
  • Lymphocyte antigen T1/Leu 1 antibody
  • T1 antibody
see all

References for Anti-CD5 + CD19 antibody [CRIS1 + CB19] (Dual color: FITC + PE) (ab1235)

ab1235 has not yet been referenced specifically in any publications.

Publishing research using ab1235? Please let us know so that we can cite the reference in this datasheet

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"